top of page
Prostate Cancer Foundation Canada - Advanced Prostate Cancer
ADVANCED PROSTATE CANCER VIDEO LIBRARY

A selection of videos from the Prostate Cancer Foundation Canada YouTube channel featuring experts from across Canada speaking on new therapies, research, and improving your quality of life while living with advanced prostate cancer.

This video library and its recordings are intended to be a helpful resource to learn more about your disease. Always discuss any treatments or trials with your healthcare provider before trying them.

Treatment advances in metastatic prostate cancer - Dr. Edmond Kwan
47:59
This video is a recording of a May 2022 Vancouver Prostate Cancer Support Group meeting. Edmond Kwan, MD, PhD is a UBC Postdoctoral Fellow in the Urologic Sciences Department, working at the Vancouver Prostate Centre. Edmond received his M.D. in 2009 and completed his Medical Oncology Training in Melbourne, Australia in 2017 with a strong interest in the care of patients with genitourinary cancers. He completed his Ph.D. at Monash University in July 2020 focusing on whole blood transcriptomics to identify biomarkers in advanced prostate cancer. His studies were supported by a scholarship from the National Health and Medical Research Council. During his Ph.D., he was actively involved in clinical research as a Principal Investigator and led various local and international clinical trials. In July 2021, supported by a UBC Killam Fellowship, he joined the Wyatt Lab at the Vancouver Prostate Centre to systemically study the genomic landscape of de novo metastatic prostate through the analysis of ctDNA and tumour tissue. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
Diagnostics and Therapeutics for Prostate Cancer: An Update - Dr. Abby Collier
01:11:29
In honour of Prostate Cancer Awareness Month, Dr. Abby Collier spoke at our Prostate Cancer Awareness Month 2021 Speaker Series. Prostate cancer (PCa) affects Canadian citizens widely and is one of the most common cancers diagnosed in either genders. As time has progressed we have become better at diagnosing and treating PCa. However scientific and medical efforts continue to push the boundaries of diagnosis and therapy. In this presentation Dr Collier will present some of the newly approved diagnostics and therapeutics for PCa, including providing a broad overview of how these fields are developing from a research and clinical trial perspective. About Dr. Collier: Originally from New Zealand, Dr. Collier holds both a BSc and PhD in pharmacology from the University of Auckland. After a postdoctoral fellowship with Professor Chris Pritsos at the University of Nevada, Dr. Collier was an assistant professor, then associate professor at the University of Hawaii Medical School. A member of the Faculty of Pharmaceutical Sciences at UBC since 2013, Dr. Collier is professor of Drug Metabolism and Pharmacokinetics, teaches pharmacology to undergraduate, graduate, pharmacy and medical students, maintains an active and well-funded research lab and directs the new undergraduate BPSc degree program. Dr. Collier's sub-specialty is drug metabolism and pharmacokinetics. She is the winner of the 2021 Center for Alternatives to Animal Testing (CAAT) Award (biennial, world-wide) in recognition of her scientific research leading the field in modeling and simulation “to reduce, refine and replace animal use”. She uses a combination of laboratory work and computer modeling to improve drug/chemical safety and efficacy. Along with her collaborators, she also performs research and publishes regularly in the fields of human and environmental toxicology and endocrinology, including prostate cancer. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of the Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
PSMA PET-CT Imaging: A Patient Perspective
01:16:36
In honour of Prostate Cancer Awareness Month, Dr. Phil Cohen, MD, FRCP(C), ABNM, joined our Coast to Coast Prostate Cancer Support Group Meeting as part of our Prostate Cancer Awareness Speaker Series. --- About Dr. Cohen: Dr. Philip Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr Cohan has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear Medicine. He is a Fellow of the Royal College of Physicians and Surgeons of Canada in Nuclear Medicine, and also of the American Board of Nuclear Medicine. Dr. Cohen is a pioneer in Nuclear Medicine in Canada and in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Dr Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, he was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
New Developments in Radiopharmaceutical Imaging and Therapy of Prostate Cancer - Dr. Arman Rahmim
01:20:10
This video is a recording of the Coast to Coast Nationwide Prostate Cancer Support Group's July 2021 meeting held over Zoom. About Arman Rahmim, PhD, DABSNM: Dr. Rahmim is Associate Professor of Radiology and Physics at the University of British Columbia (UBC) as well as Senior Scientist and Provincial Medical Imaging Physicist at BC Cancer. He received his MSc in condensed matter physics and PhD in medical imaging physics at UBC. Following doctoral studies, he was recruited by Johns Hopkins University (JHU) to lead the high resolution brain PET imaging physics program and to pursue research at the JHU Department of Radiology. In 2018, he was recruited back to Vancouver, where he conducts research in tomographic image generation and analysis, including oncologic and brain applications. He has published a book and over 150 journal articles and 300 conference proceeding papers/abstracts, and has delivered more than 100 invited lectures worldwide. He has participated as principal investigator or co-investigator on a range of grants towards quantitative tomographic imaging, including translation to clinical applications. For more information on Prostate Cancer Foundation Canada (formerly Prostate Cancer Foundation BC), please visit www.prostatecanada.ca The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
SR-BI: An essential component of steroidogenesis in castration-resistant prostate cancer - An Update
47:54
Dr. Kishor Wasan and Dr. Michael Cox, renowned researchers, are speaking on their research which investigates the use of statins, or cholesterol lowering drugs, in treating metastatic castrate resistant prostate cancer (mCPRC). --- About Dr. Kishor Wasan: PLC (Harvard Kennedy School), R.Ph., Ph.D., FAAPS, FCAHS, FCSPS Fellow Member, Royal Society of Medicine (UK) Former Dean & Professor (Retired), University of Saskatchewan Distinguished University Scholar & Adjunct Professor Co-Director & Co-Founder, NGDI-UBC Dr. Wasan has published over 240 peer-reviewed articles and 280 abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. He has won many prestigious awards and is a fellow of the American Association of Pharmaceutical Scientists and the Canadian Academy of Health Sciences. Most recently, Dr. Wasan served as the Dean of the College of Pharmacy and Nutrition at the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan is currently an Adjunct Professor and Distinguished University Scholar in the Department of Urologic Sciences, Faculty of Medicine at the University of British Columbia. He is the co-founder of the Neglected Global Diseases Initiative at UBC. Dr. Wasan led the research team at the Wasan lab at the University of British Columbia in the development of an oral formulation of amphotericin B which has successfully completed phase I human clinical trials. He will head the pharmacology program at Skymount Medical. --- About Dr. Michael Cox: Dr. Michael Cox is a molecular and cellular biologist who earned his PhD in Biochemistry from the University of North Carolina for studies on how oncogenes impact neuronal growth and differentiation. He began his work on cell signaling networks in prostate cancer at the University of Virginia. His research program is dedicated to understanding how prostate cancer, the most frequently diagnosed male malignancy, initiates and progresses and to finding ways of halting advanced disease progression. Dr. Cox’s research is funded by the Terry Fox Foundation, Canadian Cancer Society, the VGH & UBC Hospital Foundation and the Prostate Cancer Foundation of British Columbia. His work focuses on early genetic changes in prostate cells, how resulting tumor cells respond to growth factors in the presence or absence of testosterone and how these cellular changes allow prostate tumor cells to utilize these growth factors to aid development of testosterone independence. With colleagues at the Vancouver Prostate Centre and University of British Columbia, he is developing combinatorial antisense and small molecule drug strategies that decrease the responsiveness of tumor cells to growth factors and has shown that prostate cancer cells treated in this way are more sensitive to testosterone deprivation or treatment with other chemotherapies. These are first steps in developing effective treatments for patients with advanced prostate cancer. Dr. Michael Cox also serves a volunteer board member on Prostate Cancer Foundation Canada's Board of Directors. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
Finding New Therapies for Prostate Cancer - Dr. Shreyas Lingadahalli
22:54
Dr. Shreyas Lingadahalli joined the Chilliwack Prostate Cancer Support Group's December 2021 support group meeting to talk about his research in finding new therapies for prostate cancer. After medical schooling (MBBS) in India for my undergraduate studies, Dr. Lingadahalli's interest in basic and applied bio-medical research motivated him to join the MS (Biology) program at Cleveland Clinic/Cleveland State University. After obtaining his Master’s, he briefly worked as a senior research fellow in India before moving to Macau for his PhD under the supervision of Prof. Edwin Cheung. For his doctoral thesis, Dr. Lingadahalli worked on characterizing novel co-regulatory factors of AR-transcriptional complex in Prostate cancer. After completing his PhD in 2018, he moved to Vancouver Prostate Centre to join Dr. Nathan Lack’s lab for his postdoctoral training. While his work there is still aimed towards understanding the AR-mediated transcriptional regulation, he is currently focusing on defining an AR-enhancer and how mutations in these regions can affect prostate cancer. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
Medical Assistance in Dying - Dr. Michael McKenzie
38:06
Dr. McKenzie is a radiation oncologist with extensive experience in genitourinary oncology, neurooncology and palliative oncology. Additional special clinical expertise includes permanent seed implantation for localized adenocarcinoma of the prostate and both stereotactic radiosurgery and stereotactic radiation therapy for intracranial disease. Recently, he concluded a twenty-year tenure as Chair of the British Columbia Cancer Agency’s (BCCA’s) Stereotactic Working Group which oversees British Columbia’s Provincial intracranial stereotactic program. He has extensive experience conducting and leading both investigator-initiated and cooperative group clinical trials. Currently, he is a member of the Clinical Trials Committee at the National Cancer Institute of Canada’s Clinical Trials Group. After new legislation formalizing advance care planning became law in British Columbia in September 2011, Dr. McKenzie has became very active in efforts to implement that legislation at the BCCA, including those to craft a related research agenda. He is also an active member of two interprofessional research teams based at the School of Nursing at The University of British Columbia (UBC). He is a member of The Canadian Association of Radiation Oncology’s Manpower Committee. In addition, he is a member of the Clinical Promotions Committee at the Department of Surgery at UBC. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.
Theranostics in Nuclear Medicine: New Therapies for the 21st and 22nd Centuries
42:07
About Dr. Cohen: Dr. Philip Cohen is the Division Head of Nuclear Medicine at Lions Gate Hospital in Vancouver, Canada. He is the past chairman of the Diagnostic Accreditation Subcommittee for Nuclear Medicine of the British Columbia (B.C.) Medical Association and the B.C. College of Physicians, Member-at-Large of the Canadian Association of Nuclear Medicine, and Clinical Professor at the University of B.C. Dr. Cohen has numerous publications and is a member of the editorial board of the Iranian Journal of Nuclear Medicine. He is a Fellow of the Royal College of Physicians and Surgeons of Canada in Nuclear Medicine, and also of the American Board of Nuclear Medicine. Dr. Cohen is a pioneer in Nuclear Medicine in Canada and in the usage of 3-D imaging techniques to improve diagnosis of bone disease and injury in collaboration with the Medical Imaging Research Group at University of British Columbia. Dr. Cohen has been involved in clinical research trials of new radiopharmaceuticals. To that effect, he was the first recipient of a research grant from the Lions Gate Hospital Foundation, one of several peer-reviewed awards that would follow. --- The views, information, and opinions expressed in this video are those of the individuals involved and do not necessarily reflect the official policy or position of Prostate Cancer Foundation Canada (PCFC) or its employees. PCFC is not responsible and does not verify for accuracy any of the information contained in the videos available for watching on this site. The primary purpose of these videos is to educate and inform, but these videos do not constitute, or replace, medical or other professional advice.